Showing 2 of 2 Jobs
Alpharetta, GA, USA
Full-Time
Confirmed live in the last 24 hours
Provides analytics and decision tools for professionals
No salary listed
Junior, Mid
Company Historically Provides H1B Sponsorship
Alpharetta, GA, USA
This is a hybrid role that requires team members to go into the Alpharetta, GA office 2 days a week.
Get referrals →
You have ways to get a RELX referral from your network.
Applications through a referral are 3x more likely to get an interview!
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
RELX provides information-based analytics and decision tools tailored for professional and business customers across various sectors. The company operates in four key areas: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products utilize extensive data and analytics to assist clients, such as researchers, healthcare professionals, legal practitioners, and business executives, in making informed decisions and enhancing productivity. RELX's subscription-based business model ensures a consistent revenue stream, while it also earns income through transactional sales and advertising. A distinguishing feature of RELX is its commitment to corporate responsibility, focusing on diversity, social justice, and sustainable development, actively supporting the United Nations' Sustainable Development Goals through its offerings.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1894
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Mental Health Support
Family Planning Benefits
Health Savings Account/Flexible Spending Account
Flexible Work Hours
Remote Work Options
London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence
Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safetyLONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface
Trade attendees gathered in anticipation for the opening day of IASEA 2025. SINGAPORE, Apr 21, 2025 - (ACN Newswire) - The 8th edition of inter airport Southeast Asia (IASEA) was held in Singapore from 25-27 March 2025. Spanning across 6,259 sqm of exhibition space, the airport exhibition and conference brought together 3,621 industry trade professionals from 53 countries and regions, and featured 134 exhibiting companies including pavilions representing Germany, Italy, Japan and Singapore. The event saw a 43% increase in exhibitor size and a 15.6% rise in attendee numbers, underscoring the rising significance of IASEA as a platform for productive discussions. The event's achievement is also attributed to the increasing demands of operators and the rapid development and expansion of airports in Asia
Veteran Fraud Prevention Leader Joins LexisNexis Risk Solutions to Strengthen Program Integrity and Protect Public FundsWASHINGTON, April 1, 2025 /PRNewswire/ -- LexisNexis® Risk Solutions today announced the addition of Glenn Prager as Executive Director of Government Risk Solutions, reinforcing its commitment to safeguarding the integrity of our nation's critical social safety nets. Prager, a proven leader in combating fraud, waste, and abuse, brings over two decades of public and private sector experience leveraging data, analytics, and technology to ensure benefits reach those who truly need them. Glenn will work across key markets, including the U.S. Department of Health and Human Services, State and Local Medicaid Departments, and Inspector General Offices."With today's rapidly evolving fraud landscape, ensuring the integrity of federal and state benefit programs is more critical than ever," said Haywood Talcove, CEO of LexisNexis Risk Solutions – Government. "Glenn Prager's unparalleled expertise in program integrity, forensic auditing, and multi-jurisdictional fraud investigations makes him an invaluable addition to our team. His leadership will strengthen our ability to support government agencies in their mission to protect public funds, while ensuring those in need receive essential services."Prager's career has been defined by his dedication to strengthening government oversight, developing anti-fraud strategies, and enhancing compliance across Medicare, Medicaid, and other federally funded programs
Set to welcome 4,000 airport professionals, 150 international exhibitors, 4 dynamic pavilions, and 53 speakers from 66 countries and regions, IASEA 2025 is poised to shape the future of airport operations and passenger experience throughout the next 3 days. SINGAPORE, Mar 25, 2025 - (ACN Newswire) - The much-anticipated inter airport Southeast Asia (IASEA) 2025 has officially opened today at Marina Bay Sands, Singapore, bringing together key airport industry stakeholders, global solution providers, and leading experts to shape the future of airport operations and passenger experience. Themed “Airport Operations for Tomorrow”, conversations surrounding these topics are especially crucial as the aviation industry is witnessing rapid transformation and projected global passenger traffic to reach 19.5 billion by 2042
Simplify Jobs | Apply to Jobs